Can-Fite BioPharma's Namodenoson demonstrates liver-protective effects alongside its anti-cancer activity in hepatocellular carcinoma (HCC).

Analysis of the IMvigor011 study reveals that patients with high-risk muscle-invasive bladder cancer (MIBC) who maintain circulating tumor DNA-negative (ctDNA-) status post-cystectomy show favorable clinical outcomes.

NS Pharma's NS-050/NCNP-03, an antisense oligonucleotide, has been granted rare pediatric disease designation by the FDA for Duchenne muscular dystrophy (DMD) treatment.

Everest Medicines' EVER001 demonstrated an 81.8% overall clinical remission rate in the low-dose cohort and 85.7% in the high-dose cohort for pMN patients.

UroGen Pharma's UGN-102 shows an 82.3% duration of response at 12 months in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC).

The FDA has updated the labeling for Heplisav-B to include human data indicating no increased risk of major birth defects or miscarriage.

The NRG Oncology/Alliance LU005 trial found that adding atezolizumab to standard chemoradiotherapy (CRT) did not significantly improve overall survival in patients with limited-stage small-cell lung cancer (LS-SCLC).

The Phase III PADMA trial demonstrated that endocrine therapy plus palbociclib significantly improves time to treatment failure compared to mono-chemotherapy in HER2-negative/HR-positive metastatic breast cancer.

The United Kingdom has granted emergency authorization for the Pfizer-BioNTech COVID-19 vaccine, making it the first country in the world to approve its use.

Two leading CAR-T cell therapies, ciltacabtagene autoleucel and idecabtagene vicleucel, demonstrate encouraging results in treating relapsed/refractory multiple myeloma patients in earlier treatment lines.

Patient disengagement from precision medicine services often stems from fear of cancer diagnosis, language barriers, and poor care coordination, requiring improved trust-building and communication strategies.

Clinical trial costs have surged significantly, with Phase III trials in 2024 averaging $36.58 million - a 30% increase from 2018 levels, driven by growing protocol complexity and operational challenges.

Nxera Pharma has established a strategic partnership with Holling Bio-Pharma, Taiwan's largest pharmaceutical distributor, to commercialize daridorexant for insomnia treatment in the Taiwanese market.

Intrommune Therapeutics' Phase 1 OMEGA study demonstrates successful safety profile of innovative toothpaste-based peanut allergy treatment, with all participants tolerating their highest assigned dose.

Avecho Biotechnology and Sandoz have signed a 10-year exclusive licensing agreement worth up to US$19 million to develop and commercialize a CBD-based insomnia treatment for the Australian market.

Recent therapeutic advances including trifluridine/tipiracil plus bevacizumab and fruquintinib have expanded treatment options for refractory metastatic colorectal cancer patients.

The atopic dermatitis market in seven major markets is projected to reach $16.7 billion by 2030, driven by increasing disease prevalence and clinical trial advancements.

Cancer survivors face significant challenges transitioning from pediatric to adult care, with many patients becoming "lost in transition" during this critical period.

Leading pathologists highlight critical challenges in distinguishing between HER2-low and HER2-negative breast cancer cases, raising concerns about treatment decisions worth $100,000 or more.

Solventum has developed an innovative clinical trial methodology where individual teeth are enrolled as subjects, allowing multiple teeth from the same participant to be studied over time.